Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized Trial.

ABSTRACT: Background: Following SARS-CoV-2 infection, the necessity of vaccination after natural infection remains uncertain. However, many asymptomatic individuals who test negative virologically may nevertheless receive vaccination without being aware of their prior infection. Investigating the implications for vaccine safety and efficacy is crucial. Methods: We analyzed the daily fluctuations in anti-SARS-CoV-2 IgG antibody levels during the enrollment period of a phase 3 randomized, double-blinded, placebo-controlled clinical trial of a tetravalent COVID-19 protein vaccine, SCTV01E. Additionally, we investigated the relationship between baseline IgG levels and their protection against COVID-19 in participants who received placebo. Results: The daily enrolled participants wit

SUBMITTER: Yan L 

PROVIDER: S-EPMC12474267 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature